Stocks › IONS
IONIS PHARMACEUTICALS INC
IONS·Nasdaq·
United States·USD
United States·USD$44.16
+0.16 (+0.36%)
Close · Oct 7, 2026 · Close Prices from Tiingo.com
IONS
IONIS PHARMACEUTICALS INC · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
IONSS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of IONS by members of U.S. Congress · 12 on record
Whale Activity
Position changes in IONS reported for 2026-06-30 by 11 tracked institutional filers
- Increased6
- New0
- Held0
- Decreased4
- Closed0
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 10.7M | $848.8M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 7.9M | $623.2M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.2M | $571.8M | increased |
| TWO SIGMA INVESTMENTS, LP | 6.3M | $495.7M | increased |
| CITADEL ADVISORS LLC | 86.5M | $134.7M | increased |
| RENAISSANCE TECHNOLOGIES LLC | 559.4K | $44.4M | increased |
| D. E. Shaw & Co., Inc. | 297.0K | $23.6M | decreased |
| MILLENNIUM MANAGEMENT LLC | 288.9K | $22.9M | decreased |
| CITADEL ADVISORS LLC | 236.3K | $18.7M | decreased |
| BlackRock, Inc. | 11.4M | $17.8M | decreased |
| Tetragon Partners GP Ltd | 97.2K | $7.7M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by IONS insiders, by quarter · Form 4
Recent Insider Transactions
1,676 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Hayden Michael RDirector · Director | Purchase | +5,000 | $51.60 | $258K | Jul 31, 2026 | Form 4 ↗ |
| Hayden Michael RDirector · Director | Purchase | +15.0K | $53.38 | $801K | Jul 30, 2026 | Form 4 ↗ |
| BENNETT C FRANKEVP, Chief Scientific Officer | Sale | −5,536 | $83.58 | $463K | Jul 7, 2026 | Form 4 ↗ |
| BENNETT C FRANKEVP, Chief Scientific Officer | Sale | −15.0K | $85.46 | $1.3M | Jul 7, 2026 | Form 4 ↗ |
| Diaz Allene M.Director · Director | Sale | −10.1K | $85.42 | $864K | Jul 7, 2026 | Form 4 ↗ |
| Kordasiewicz Holly B.EVP, Chief Development Officer | Sale | −362 | $84.30 | $31K | Jul 7, 2026 | Form 4 ↗ |
| KLEIN JOSEPH IIIDirector · Director | Sale | −99 | $79.45 | $8K | Jul 1, 2026 | Form 4 ↗ |
| KLEIN JOSEPH IIIDirector · Director | Sale | −11.4K | $79.04 | $903K | Jul 1, 2026 | Form 4 ↗ |
| Baroldi JosephEVP, Chief Business Officer | Sale | −5,635 | $80.16 | $452K | Jun 26, 2026 | Form 4 ↗ |
| Baroldi JosephEVP, Chief Business Officer | Option exercise | +1,769 | $32.60 | $58K | Jun 26, 2026 | Form 4 ↗ |
| Baroldi JosephEVP, Chief Business Officer | Option exercise | +3,866 | $56.78 | $220K | Jun 26, 2026 | Form 4 ↗ |
| O'NEIL PATRICK R.EVP CLO & General Counsel | Sale | −3,069 | $80.00 | $246K | Jun 26, 2026 | Form 4 ↗ |
| Schneider EugeneEVP, Chf Clinical Develop Ofcr | Sale | −26.0K | $81.05 | $2.1M | Jun 26, 2026 | Form 4 ↗ |
| Schneider EugeneEVP, Chf Clinical Develop Ofcr | Option exercise | +26.0K | $60.89 | $1.6M | Jun 26, 2026 | Form 4 ↗ |
| Monia Brett PChief Executive Officer · Director | Sale | −50.0K | $80.59 | $4.0M | Jun 26, 2026 | Form 4 ↗ |
| Monia Brett PChief Executive Officer · Director | Option exercise | +50.0K | $56.78 | $2.8M | Jun 26, 2026 | Form 4 ↗ |
| Monia Brett PChief Executive Officer · Director | Sale | −21.1K | $78.49 | $1.7M | Jun 25, 2026 | Form 4 ↗ |
| Monia Brett PChief Executive Officer · Director | Option exercise | +21.1K | $32.60 | $687K | Jun 25, 2026 | Form 4 ↗ |
| Swayze EricEVP Research | Sale | −10.6K | $79.18 | $839K | Jun 25, 2026 | Form 4 ↗ |
| Monia Brett PChief Executive Officer · Director | Sale | −14.6K | $78.41 | $1.1M | Jun 24, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding IONS · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Fidelity Growth Company Fund Fidelity Mt. Vernon Street Trust | 8.5M | $648.1M | 0.66% | May 31, 2026 |
| Growth Fund of America | 7.7M | $586.7M | 0.16% | May 31, 2026 |
| SMALLCAP World Fund Inc | 5.3M | $417.1M | 0.44% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 5.0M | $395.6M | 0.02% | Jun 30, 2026 |
| New Economy Fund | 4.9M | $372.5M | 0.72% | May 31, 2026 |
| VANGUARD HEALTH CARE FUND VANGUARD SPECIALIZED FUNDS | 6.2M | $321.6M | 0.84% | Jul 31, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 3.6M | $285.3M | 0.15% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund Fidelity Mt. Vernon Street Trust | 2.3M | $179.7M | 0.65% | May 31, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 2.1M | $164.6M | 0.35% | Jun 30, 2026 |
| Fidelity Series Growth Company Fund Fidelity Mt. Vernon Street Trust | 2.1M | $159.9M | 0.65% | May 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list IONS's shares (CUSIP 462222100), each fund at its latest report since Mar 8, 2026, largest positions first. Bonds, options and short positions are left out.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming ionis pharmaceuticals as client
- IONIS PHARMACEUTICALS, INC.IONIS PHARMACEUTICALS, INC. · 2026 Q2 · MMM, TAX, HCR$150K
Filing ↗ - LMH STRATEGIC SOLUTIONSIONIS PHARMACEUTICALS, INC. · 2026 Q2 · HCR$30K
Filing ↗ - LMH STRATEGIC SOLUTIONSIONIS PHARMACEUTICALS, INC. · 2026 Q1 · HCR$30K
Filing ↗ - IONIS PHARMACEUTICALS, INC.IONIS PHARMACEUTICALS, INC. · 2026 Q1 · HCR, MMM, TAX$150K
Filing ↗ - IONIS PHARMACEUTICALS, INC.IONIS PHARMACEUTICALS, INC. · 2025 Q4 · HCR, MMM, TAX$140K
Filing ↗
Government Contracts
Federal awards to IONIS PHARMACEUTICALS INC · USAspending
No federal contract awards found for IONIS PHARMACEUTICALS INC.
U.S. Patents
Recent USPTO applications naming IONIS PHARMACEUTICALS INC
No USPTO patent applications found for IONIS PHARMACEUTICALS INC.
Annual Financials
From IONS's 10-K filings · XBRL
No annual XBRL figures on record for IONS. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in IONS's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsSep 23, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsSep 4, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsSep 4, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 29, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsJul 9, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsJun 24, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJun 12, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 7.01, 9.01Officer / director change · Shareholder vote · Reg FD disclosureJun 8, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsMay 28, 2026
EDGAR ↗
About IONIS PHARMACEUTICALS INC
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersCARLSBAD, CA
IncorporatedCA
SEC CIK0000874015 ↗
Former namesISIS PHARMACEUTICALS INC